• Inovio Pharmaceuticals received FDA accelerated approval for VOCERYQ, its first product, for adults with RRP.
• The treatment reduces the need for surgery by targeting the underlying viral cause of RRP.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.